PEMRYDI RTU(pemetrexed injection)
Recall D-0765-2026, part of FDA recall event 99530. See Shilpa Medicare's company page.
Shilpa Medicare Limited started this Class II drug recall on Jul 29, 2026 (voluntary: firm initiated); FDA lists it as ongoing.
- Classification: Class II
- Started: Jul 29, 2026
- Status: Ongoing
- Products in this event: 2
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials
- Product
- PEMRYDI RTU(pemetrexed injection), 500 mg/50 mL (10 mg/mL), Single-dose vial, Rx only, Manufactured by: Zydus Lifesciences Limited, Ahmedabad, India; Distributed by: Amneal Pharmaceuticals LC, Bridgewater, NY 08807. NDC: 70121-2461-1
- Quantity
- 9,489 50mL vials
- Lots and codes
- Lot: P400157, Exp 08/31/2026; Lot PA00047A, Exp 09/30/2027
- Distribution
- Nationwide in the USA.
- Recalling firm
- Shilpa Medicare Limited, Jadcherla, Mahabubnagar District, India
- How the firm notified
- Letter
- FDA classified
- Aug 14, 2026
- PEMRYDI RTU (pemetrexed injection), 100 mg/10 mL (10 mg/mL), Single-dose vial, Rx only, Manufactured by: Zydus…D-0764-2026 · Class II · Jul 29, 2026 · Ongoing
Newest first, one product per recall event; search them all
- Imatinib Mesylate Tablets 100 mg, Rx Only, 90-count Bottle, Manufactured by: Shilpa Medicare Limited, India,…D-0124-2021 · Class II · Dec 8, 2020 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports